Trial
NCT05048940
Efficacy, Safety, and Immunogenicity of Vaccine Reimmunization With a Third Homologous Versus Heterologous Dose Against COVID-19 in Patients Undergoing Solid Organ Transplantation.
Phase IIIWITHDRAWNREGULATORYConfidence: MEDIUM
Sponsor
Instituto de Investigación Marqués de Valdecilla
Collaborators
—
Condition
Covid19
Intervention
Janssen vaccine
Why stopped
The health authority indicates that the official vaccination schedule differs from that described in the protocol.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-03-02